Concert Pharmaceuticals Reports 2021 Financial Results and Provides Company Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Concert Pharma (CNCE) Misses Q4 EPS by 28c
March 3, 2022 6:09 AM ESTConcert Pharma (NASDAQ: CNCE) reported Q4 EPS of ($1.01), $0.28 worse than the analyst estimate of ($0.73). Revenue for the quarter came in at $13 thousand versus the consensus estimate of $20 thousand.
For earnings history and earnings-related data on Concert Pharma (CNCE) click here.
... More